{"id":537964,"date":"2021-09-14T09:03:05","date_gmt":"2021-09-14T13:03:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\/"},"modified":"2021-09-14T09:03:05","modified_gmt":"2021-09-14T13:03:05","slug":"edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\/","title":{"rendered":"Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1&#215;1 Event on September 23"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1&#215;1 Event on September 23<\/b><\/p>\n<p>BOULDER, Colo.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nEdgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1\u00d71 Event, on September 23, 2021. During the event, members of the Company\u2019s leadership team will engage in 1\u00d71 investor meetings. Please contact your SVB Leerink representative to schedule a virtual one-on-one meeting with Edgewise.\n<\/p>\n<p><b>About Edgewise Therapeutics<\/b><\/p>\n<p>\nEdgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise\u2019s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.<b \/>To learn more, go to: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.edgewisetx.com&amp;esheet=52489816&amp;newsitemid=20210914005033&amp;lan=en-US&amp;anchor=www.edgewisetx.com&amp;index=1&amp;md5=1a867601598e9e73c755eefa0962a528\">www.edgewisetx.com<\/a> or follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fedgewisetx&amp;esheet=52489816&amp;newsitemid=20210914005033&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=2&amp;md5=48c4338fe23b53fb86c449915897ff27\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FEdgewiseTx&amp;esheet=52489816&amp;newsitemid=20210914005033&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=c195053d86f0a2dcaf0d38718536e1c5\">Twitter<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FEdgewisetx&amp;esheet=52489816&amp;newsitemid=20210914005033&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=e4e02f370f347414200cab39c1de8645\">Facebook<\/a>.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210914005033r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210914005033\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210914005033\/en\/<\/a><\/span><\/p>\n<p><b>Investors &amp; Media<br \/>\n<\/b><br \/>Michael Carruthers<br \/>\n<br \/>Chief Financial Officer<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@edgewisetx.com\">ir@edgewisetx.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Colorado<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Pharmaceutical Clinical Trials Cardiology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210914005033\/en\/743983\/3\/Edgewise_Logo_-_JPG.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1&#215;1 Event on September 23 BOULDER, Colo.&#8211;(BUSINESS WIRE)&#8211; Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1\u00d71 Event, on September 23, 2021. During the event, members of the Company\u2019s leadership team will engage in 1\u00d71 investor meetings. Please contact your SVB Leerink representative to schedule a virtual one-on-one meeting with Edgewise. About Edgewise Therapeutics Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1&#215;1 Event on September 23&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-537964","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1x1 Event on September 23 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1x1 Event on September 23 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1&#215;1 Event on September 23 BOULDER, Colo.&#8211;(BUSINESS WIRE)&#8211; Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1\u00d71 Event, on September 23, 2021. During the event, members of the Company\u2019s leadership team will engage in 1\u00d71 investor meetings. Please contact your SVB Leerink representative to schedule a virtual one-on-one meeting with Edgewise. About Edgewise Therapeutics Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development &hellip; Continue reading &quot;Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1&#215;1 Event on September 23&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-14T13:03:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210914005033r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1&#215;1 Event on September 23\",\"datePublished\":\"2021-09-14T13:03:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\\\/\"},\"wordCount\":288,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210914005033r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\\\/\",\"name\":\"Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1x1 Event on September 23 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210914005033r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-09-14T13:03:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210914005033r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210914005033r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1&#215;1 Event on September 23\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1x1 Event on September 23 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\/","og_locale":"en_US","og_type":"article","og_title":"Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1x1 Event on September 23 - Market Newsdesk","og_description":"Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1&#215;1 Event on September 23 BOULDER, Colo.&#8211;(BUSINESS WIRE)&#8211; Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1\u00d71 Event, on September 23, 2021. During the event, members of the Company\u2019s leadership team will engage in 1\u00d71 investor meetings. Please contact your SVB Leerink representative to schedule a virtual one-on-one meeting with Edgewise. About Edgewise Therapeutics Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development &hellip; Continue reading \"Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1&#215;1 Event on September 23\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-14T13:03:05+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210914005033r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1&#215;1 Event on September 23","datePublished":"2021-09-14T13:03:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\/"},"wordCount":288,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210914005033r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\/","name":"Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1x1 Event on September 23 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210914005033r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-09-14T13:03:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210914005033r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210914005033r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-participate-at-svb-leerink-cyberx-series-neuromuscular-rare-diseases-genetic-medicines-1x1-event-on-september-23\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1&#215;1 Event on September 23"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/537964","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=537964"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/537964\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=537964"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=537964"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=537964"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}